TNFRSF10B and cancer: Among DRs, death receptor 5 (DR5), also known as TRAIL-R2 or KILLER receptor, is the most promising candidate to develop a targeted therapy against cancer, since its expression level is significantly higher in cancer cells compared to that of healthy cells.